PPIDT00014

Drug Information
NameGoserelin
SequencepEHWSYdS(tBu)LRPAzGlyNH₂
DrugBank_IDDB00014
Typesmall molecule
IndicationGoserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prostate - The management of endometriosis - Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding - Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women

Dosage Forms
Form Route Strength
Implant
Implant Parenteral; Subcutaneous
10.8 MG
Implant Parenteral; Subcutaneous
3.6 MG
Implant Subcutaneous
10.8 mg/1
Implant Subcutaneous
3.6 mg
Implant Subcutaneous
3.6 mg/1
Implant Subcutaneous
360000 mg
Implant Subcutaneous
1080000 mg
Implant
10.8 mg
Implant
3.6 mg
Injection Subcutaneous
3.6 mg
Implant Subcutaneous
10.8 mg
Injection Subcutaneous
10.8 mg
Solution
3.6 mg
Solution
10.8 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P22888 LHCGR Lutropin-choriogonadotropic hormone receptor Homo sapiens agonist Link
target P01148 GNRH1 Progonadoliberin-1 Homo sapiens activator Link
target P30968 GNRHR Gonadotropin-releasing hormone receptor Homo sapiens agonist Link